Response to "clinical relevance of CYP3A5 genotype on maraviroc exposures"

Drug Metab Dispos. 2015 May;43(5):773. doi: 10.1124/dmd.115.064188.

¹ Division of Clinical Pharmacology, Departments of Medicine (Y.L., E.J.F., C.W.H., N.N.B.) and Pharmacology and Molecular Sciences (Y.L., C.W.H., N.N.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Division of Clinical Pharmacology, Departments of Medicine (Y.L., E.J.F., C.W.H., N.N.B.) and Pharmacology and Molecular Sciences (Y.L., C.W.H., N.N.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland nbumpus1@jhmi.edu.

No abstract available

Publication types